Physician profile
Paul E Cox
NPI 1841291895
$2,334.27
in general payments reported to CMS, 2019-2025
12 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $88.56 · 2021: $561 · 2022: $292 · 2023: $428 · 2024: $205 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.20 |
| Education | $154.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.25 | 2023-2025 | Botox, Ubrelvy, Synthroid |
| Allergan, INC. | $434.57 | 2019-2022 | |
| Galderma Laboratories, L.P. | $427.41 | 2019-2025 | |
| Merz North America, INC. | $355.23 | 2021-2022 | |
| Astellas Pharma US INC | $128.63 | 2025 | Veozah |
| Novo Nordisk INC | $123.12 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $91.01 | 2025 | Nexletol |
| Exact Sciences Corporation | $73.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $33.43 | 2021 | |
| Lilly USA, LLC | $16.02 | 2025 | Zepbound |
| Virtus Pharmaceuticals LLC | $12.91 | 2021 | |
| Currax Pharmaceuticals LLC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.